[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 26, Issue 1 (4-2024) ::
2024, 26(1): 1-10 Back to browse issues page
Examining the Effect of Probiotics on Glycemic Indices and Blood Lipid Profiles in Prediabetic Individuals: A Double-blind Clinical Trial
S Kalbasi , SM Motalebi , A Erfanifar , S Omidvari , H Borhany
Department of Internal Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran , dr_motalebi@yahoo.com
Abstract:   (166 Views)
Introduction: Prediabetes is an intermediate stage between normal glucose regulation and type 2 diabetes mellitus (T2DM), characterized by elevated blood glucose levels but not high enough for a diabetes diagnosis. Recent evidence suggests that probiotics may be promising approaches to improving this condition. This study aimed to investigate the probiotic use's effect on prediabetic individuals' metabolic indices. Materials and Methods: In this double-blind clinical trial, prediabetic patients referred to Loghman Hakim Hospital were examined. Patients were randomly divided into two groups: one received the probiotic drug Biodiab (produced by Novagen Pharmaceutical Company - with Takgene Holding) alongside standard diabetes care, and the other received a maltodextrin placebo. After three months, patients' metabolic indices were reassessed. Results: The results showed a significant reduction in fasting blood sugar (FBS) (P: 0.024) and hemoglobin A1C (HBA1C) (P: 0.01) levels in the probiotic group compared to the placebo group. The probiotic group exhibited a mean reduction in fasting blood sugar of 5.50 ± 1.2 mg/dL. Additionally, the mean reduction in HBA1C in the probiotic group was 0.31±0.04%, with an absolute difference of 0.34% between the two groups (0.18 to 0.50 with CI95%). However, no significant differences were found in lipid profile, weight, or systolic and diastolic blood pressure between the two groups. Conclusion: This study indicates that probiotics may effectively manage glycemic parameters in prediabetic individuals, suggesting their potential as a therapeutic strategy to mitigate the risk of developing diabetes.
Keywords: Prediabetic Patients, Probiotics, Fasting Blood Sugar, Lipid Profile
Full-Text [PDF 889 kb]   (107 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2024/02/12 | Accepted: 2024/11/16 | Published: 2024/04/29
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kalbasi S, Motalebi S, Erfanifar A, Omidvari S, Borhany H. Examining the Effect of Probiotics on Glycemic Indices and Blood Lipid Profiles in Prediabetic Individuals: A Double-blind Clinical Trial. Iranian Journal of Endocrinology and Metabolism 2024; 26 (1) :1-10
URL: http://ijem.sbmu.ac.ir/article-1-3149-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 26, Issue 1 (4-2024) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.1 seconds with 38 queries by YEKTAWEB 4691